Comparing two ovarian suppression drugs for breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests two hormone-blocking injections (leuprolide and goserelin) to suppress ovarian function in premenopausal women with breast cancer. It aims to see how well these drugs work when taken with standard hormone pills.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You are pre- or peri-menopausal (still having periods or your estrogen levels are in the premenopausal range).
- You plan to take a GnRH agonist (such as leuprolide or goserelin) along with a hormone-blocking pill (like tamoxifen or anastrozole) for breast cancer treatment.
- You have not had both ovaries removed in the past.
- If you had chemotherapy, it must be completed. You can still take certain other targeted therapies (like trastuzumab or CDK4/6 inhibitors).
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether giving the drug goserelin in a different spot on the body works just as well for suppressing ovarian function in premenopausal women with hormone receptor positive breast cancer. You may be a fit if you've already been on goserelin shots in your abdomen for at least 6 months.
This study tests whether switching the type of ovarian-suppressing medication helps keep hormone-sensitive breast cancer under control in younger women. You'll be screened to see if your current treatment is working, then potentially switched to a different formulation to see if it works better.
This trial tests whether combining immunotherapy, hormone therapy, and an AKT-blocking drug can control ER-positive advanced breast cancer in women whose cancer is resistant to hormone treatment. It may help shrink tumors and slow disease by targeting several pathways at once.
This study looks at how well women with hormone receptor-positive breast cancer follow the plan for ovarian suppression therapy (medication to lower estrogen). It aims to help doctors understand real-world treatment patterns and improve care.
This trial tests whether adding a hormone-blocking drug (GnRH agonist) to standard chemotherapy before surgery helps premenopausal women with triple-negative breast cancer. It aims to improve treatment outcomes by targeting hormones that may fuel tumor growth.
This Phase 3 trial compares hormone-based treatment versus chemotherapy given before surgery in people who are premenopausal and have hormone-receptor positive, HER2-negative breast cancer. It looks to see which approach works better to control the cancer before the breast operation.
Hear when a new Anatomic Stage I Breast Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.